{
    "nctId": "NCT00194792",
    "briefTitle": "Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer",
    "officialTitle": "Neoadjuvant Complete Hormonal Blockade Followed by Neoadjuvant Chemotherapy for Resectable Hormone Receptor Positive, HER-2/Neu Negative Breast Cancer, A Phase II Study",
    "overallStatus": "TERMINATED",
    "conditions": "Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 28,
    "primaryOutcomeMeasure": "Number of Participants With Clinical Response",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Have histologically confirmed, operable ER or PR +, HER2/neu negative, radiographically measurable breast cancer \\> 1cm (Operable lesions are T1c - T3 and N0 - N2a; histologic confirmation should be by core needle biopsy only)\n* Be chemotherapy naive\n* Have an ECOG performance status of =\\< 2\n* Be assessed for menopausal status (For study purposes, postmenopausal is defined as: a prior documented bilateral oophorectomy, or a history of at least 12 months without spontaneous menstrual bleeding, or age 60 or older with a prior hysterectomy without oophorectomy, or Age less than 60 with a prior hysterectomy without oophorectomy \\[or in whom the status of the ovaries is unknown\\], with a documented FSH level demonstrating confirmatory elevation in the postmenopausal range for the lab)\n* All premenopausal patients must have a baseline FSH and LH\n* ANC \\>= 1,500\n* Platelet count \\>= 100,000\n* Serum creatinine =\\< 1.5 x IULN\n* Estimated creatinine clearance \\> 50 ml/min\n* Have staging studies and tumor assessment prior to registration\n* Bone density exam must be done within the first 3 months of complete hormonal blockade\n* Have a negative pregnancy test within seven days prior to registration if of childbearing potential\n* Be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study specific screening procedures\n\nExclusion Criteria:\n\n* Primary tumor =\\< 1 cm, not measurable; inflammatory disease\n* Pregnant or lactating; women of childbearing potential with either a positive or no pregnancy test at baseline are excluded (Women of childbearing potential who are not using a reliable and appropriate contraceptive method are excluded; patients must agree to continue contraception for 30 days from the last study drug administration)\n* Prior unanticipated severe reaction to fluoropyrimidine therapy, or known sensitivity to 5-fluorouracil\n* Previous enrollment in an investigational drug study within the last 4 weeks\n* Evidence of distant metastatic disease\n* Prior chemotherapy or hormonal therapy for breast cancer\n* Prior malignancy other than adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, other stage I or II cancer from which the patient has been disease free for at least 5 years\n* History of uncontrolled seizures, central nervous system disorders, or psychiatric disability judged by the investigator to be clinically significant, precluding informed consent, or interfering with compliance with oral drug intake\n* Any other life-threatening illness (e.g. serious, uncontrolled concurrent infection or clinically significant cardiac disease - congestive heart failure, symptomatic coronary artery disease, cardiac arrhythmia not well controlled with medication or myocardial infarction\n* Major surgery within four weeks of the start of study treatment without complete recovery\n* Lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome\n* Known, existing uncontrolled coagulopathy\n* Unwillingness to give informed consent\n* Unwillingness to participate or inability to comply with the protocol for the duration of the study",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}